BioCentury | Jun 23, 2016
Distillery Therapeutics

Therapeutics: Integrin avβ3 (CD51/CD61)

...neck cancer and lung cancer and preclinical testing to treat melanoma. Tactic Pharma LLC has ATN-161...
BioCentury | Apr 10, 2014
Cover Story

Pre-EMP-tive strike against GBM

...for mesothelioma and NSCLC; Phase I for ovarian cancer and solid tumors Tactic Pharma LLC ATN-161...
BioCentury | Jul 16, 2012
Company News

Tactic Pharma, Wilson Therapeutics deal

...melanoma and myeloma. Tactic will become a shareholder in Wilson. Details were not disclosed. Tactic's ATN-161...
...Andrew Mazar said after it finalizes funding the company could start Phase II trials with ATN-161...
BioCentury | May 29, 2008
Targets & Mechanisms

Swell Effect on Glioma

...irinotecan is on the way to becoming the new standard of care." Attenuon is developing ATN-161...
BioCentury | Apr 10, 2008
Cover Story

Metastasis, Interrupted

...a primary tumor is macroscopically detectable, it may well already have intravasized and metastasized." Attenuon's ATN-161...
BioCentury | Apr 5, 2004
Clinical News

Attenuon preclinical data

...animals treated with ATN-161 regressed or grew significantly more slowly than tumors in control animals. ATN-161...
...American Association for Cancer Research meeting in Orlando. Attenuon LLC , San Diego, Calif. Product: ATN-161...
Items per page:
1 - 6 of 6